Product Code: BIO022H
The global market for botanical and plant-derived drugs will grow from $29.4 billion in 2017 to around $39.6 billion by 2022 with a compound annual growth rate (CAGR) of 6.1% for the period of 2017-2022.
- An overview of the botanical drug industry, with the overall plant-derived drug industry as a backdrop and the global market for these drugs going forward
- Analyses of global market trends, with data from 2016, estimates for 2017, and projections of compound annual growth rates (CAGRs) through 2022
- A focus on legal, prescription-required therapeutic medicines sold in the open market; the study does not specifically cover herbals generally sold as dietary supplements (i.e., to promote overall “wellness” rather than to address specific medical conditions or symptoms)
- Examination of the industry structure, competition, and market drivers
- Discussion of market size and segmentation, including breakdowns of sales by therapeutic area and geographic area
- Observations and conclusions regarding the future of the botanical and plant-derived drug industry
This report is an analytical business tool whose primary purpose is to describe the botanical drug industry with the overall plant-derived drug industry as a backdrop and the global market for these drugs going forward.
For the purposes of this report, botanicals are those drugs that are FDA-approved under the botanical drug pathway, while plant-derived drugs are both botanicals as well as other approved drugs that contain a mixture of natural plant-derived and synthetic or semisynthetic substances.
The study's main focus is on legal, prescription-required therapeutic medicines sold in the open market. The study does not specifically cover herbals generally sold as dietary supplements (i.e., to promote overall “wellness” rather than to address a specific medical condition or symptoms). While there is a substantial market for these products, the medical value of many of these substances has not been demonstrated conclusively.
The study also does not cover the following:
- Underground or illicit drugs.
- Drugs derived from Archaea, bacteria and fungi (molds and yeasts).
- Nonmedicinal plant substances, such as laxative cellulose and pectin fiber.
- Intravenously delivered nutrients of plant origin, such as dextrose.
- Plant-derived substances serving as pharmaceutical excipients, such as starch, methylcellulose, guar gum, vegetable oils, fatty acids, cocoa butter and candelilla wax.
- Plant substances serving in cosmetics, toiletries and personal care products.
- Microbial fermentation products, even those made with culture media incorporating corn steep liquor, starch or other plant-derived nutrients.
The format of the study is organized around the following topics:
- Major types and applications of botanical drugs with plant-derived drugs as their backdrop.
- Market size and segmentation, including the breakdown of sales by therapeutic area and geographic area.
- Market projections through 2022.
- Observations and conclusions regarding the future of the botanical and plant-derived drug industry.
Kim Lawson is a graduate of Mount Holyoke College with a degree in English Literature and an M.A. in management from Harvard University's extension program. She acquired experience as a healthcare journalist, including working for John Wiley & Sons as a print reporter, before serving as a research analyst in a small market research firm (in the Research Triangle Park area of North Carolina) that focused on pharmaceuticals and biotechnology. Before joining that firm, she published two reports on emerging and established diagnostics and therapeutics for benign and cancerous breast disease.
Table of Contents
Chapter 1: Introduction
- Study Goals and Objectives
- Reasons for Doing This Study
- Scope of Report
- Information Sources
- Geographic Breakdown
- Analyst's Credentials
- Related BCC Research Reports
Chapter 2: Summary and Highlights
- Trends and Drivers for Botanical Drug Development
Chapter 3: Market and Technology Background
- Brief History of Plant-Derived Medicines
- Opportunity Lies Beyond What Is Known
- Getting Started
- Key Drivers
- Key Challenges
- U.S. Government Investment
- Industry Investment
- Nutrition Science Partners Ltd. (Nestlé Health): A Case Study
- Botanical Drugs Defined
- Understanding the Regulatory Process
- Investigational New Drug Applications
- Clinical Trials
- New Drug Application
- The First and Second U.S. Approved Botanical Drug
- Veregen (Chinese Green Tea Catechins)
- Mytesi, Formerly Fulyzaq (Crofelemer)
- Botanical Candidates in the Pipeline
- Danshen Dripping Pill (Cardiotonic Pill)
- EISO (East Indian Sandalwood Oil)
- Microbio and WH-1, MB-6 and OB318
- A Growing Pipeline
- Overall Pharma Landscape
- Major Classes of Plant Drugs
- Terpenes and Steroids
- Alkaloids and Glycosides
- The Emergence of Cannabinoids
- Intellectual Property
- A New Type of Production: Plant-Made Drugs
- Moving Production Forward
- Supply and Legal Issues
- Drug Development and Manufacture
Chapter 4: Market Breakdown by Technology Type
- Sales of Plant-derived Drugs by Region
- Plant-derived Drugs by Therapeutic Area
- Value of Plant-derived Drugs by Therapeutic Area
- A Pipeline Perspective: Composition of Botanical Drugs in Clinical Development
Chapter 5: New Developments and Market Opportunities
- Hormone Therapy and Metabolism Applications
- Infectious Disease Applications
- Pain and Central Nervous System Disease Applications
- Cardiovascular and Metabolic Applications
- Respiratory, Inflammation (Both Nonrelated and Related to Orthopedic) and Autoimmune Applications
- Dermatology Applications
- Gastrointestinal Applications
- Oncology Applications
- Botanical Drugs in Clinical Development
- Promising Candidates for Botanical Drugs
Chapter 6: Company Profiles
Chapter 7: Appendix
About BCC Research
- About BCC Research
- BCC Membership
- BCC Custom Research
List of Tables
- Summary Table: Global Market for Botanical and Plant-derived Drugs*, by Type, Through 2022 ($ Millions)
- Table 1: Key Events Related to Botanical Medicine
- Table 2: Notable Plant-derived Drugs
- Table 3: Number of Botanicals Pre-INDS and INDs Submitted to the FDA, by Type, Through 2013 (Units)
- Table 4: SWOT Analysis of Botanical Drug Development
- Table 5: Key Investments in Botanical and Other Plant-derived Drugs
- Table 6: Distinctions Among Products That Use Plants Medicinally
- Table 7: Botanical Composition of Menerba (MF 101)*
- Table 8: Top Pharma Companies, by Revenue, 2016 ($ Billions)
- Table 9: Major Upcoming U.S. Patent Expiries, 2014-2022
- Table 10: Major Producers of Raw Materials for Plant-Based Medicine
- Table 11: Key Companies with Natural Product Libraries
- Table 12: Number of FDA-Approved Botanical Drugs, Through 2022
- Table 13: Global FDA-Approved Botanical Drugs Market, by Therapeutic Area, Through 2022 ($ Millions)
- Table 14: Plant-derived Hormone Therapy and Metabolism Drugs in Late-Stage Development
- Table 15: Plant-derived Infectious Disease Drugs in Late-Stage Development
- Table 16: Brain Disorders That are Refractory to Small Molecule Drugs
- Table 17: Plant-derived Pain and CNS Drugs in Late-Stage Development
- Table 18: Plant-derived Cardiovascular and Metabolic Drugs in Late-Stage Development
- Table 19: Plant-Derived Respiratory, Inflammation (Both Nonrelated and Related to Orthopedic) and Autoimmune Drugs in Late-Stage Development
- Table 20: Plant-derived Dermatology/Wound Care Drugs in Late-Stage Development
- Table 21: Plant-derived Gastrointestinal Drugs in Late-Stage Development
- Table 22: Estimated U.S. New Cancer Cases, by Gender, 2016
- Table 23: Plant-derived Oncology Drugs in Late-Stage Development
- Table 24: Botanical Drugs in Clinical Development with Possible FDA-Approved Commercialization, Through 2022
- Table 25: Promising Compounds Being Studied for Medicinal/Therapeutic Potential
- Table 26: Plant-derived Drugs: Their Origin and Actions
- Table 27: Useful Resources for the Botanical Industry
List of Figures
- Summary Figure: Global Market for Botanical and Plant-derived Drugs*, by Type, 2016-2022 ($ Millions)
- Figure 1: Top Therapeutic Areas of FDA Drug Approvals, 2016 (Number, Total = 22)
- Figure 2: Composition of FDA-Approved Botanical Indications, by Therapeutic Area, 2017 and 2022 (No./%)
- Figure 3: Global FDA-Approved Botanical Drugs Market, by Therapeutic Area, 2017 and 2022 ($ Millions)
- Figure 4: Therapeutic Areas Targeted for Botanical Drugs in Phase 2 or Later, 2017* (%)